

Annual General Meeting of Shareholders – Lavipharm S.A.: New Chair of the Board and First Dividend Distribution in 18 Years

Paiania, 3 July 2025 - Lavipharm S.A. (LAVI) held its Annual General Meeting at the company's headquarters in Paiania, with a quorum achieved, as 34 shareholders representing 70,34% of the share capital were present.

CEO Tilemachos Lavidas opened the session by welcoming shareholders and announcing the departure of Mr. Minas Tanes as Chairman of the Board. He expressed appreciation for Mr. Tanes' years of dedicated service and his vital role in the company's growth. The new Chair of the Board is **Ms. Sofia Kounenaki-Efraimoglou**, the first woman to hold this position in Lavipharm's history.

Mr. Lavidas reflected on Lavipharm's business transformation and the strategic partnerships that have driven sales growth and profitability in 2024. He emphasized the importance of the company's first dividend distribution in 18 years, marking a key milestone in Lavipharm's financial evolution. With a clear vision to double revenue once again in the coming years, he noted that the company is now fully on a growth trajectory and extended sincere thanks to Lavipharm's employees.

Ms. Kounenaki-Efraimoglou addressed the shareholders, underscored her commitment to sustainable growth and innovation. "With clear priorities, a disciplined execution plan, and a strong sense of purpose, Lavipharm is well-positioned to lead its industry, delivering long-term value to its shareholders," she noted.

Deputy CEO Panagiotis Giannouleas presented Lavipharm's 2024 business overview, highlighting the company's substantial market share growth in recent years. He also marked the successful completion of the first phase of Lavipharm's recovery, which included an organizational restructuring that significantly reduced complexity and sharpened the company's focus on areas of competitive advantage. These efforts have positioned Lavipharm as one of the most notable turnaround and success stories in the industry.

Building on this momentum, Mr. Giannouleas announced that Lavipharm is entering a second, more dynamic phase, aiming to double its revenue over the coming years. This growth will be driven by the launch of new prescription and over-the-counter products in the Greek market, along with the full deployment of strategic partnerships, particularly with Tikun Olam in medical cannabis and INOVA, which is expected to support further international expansion. He added that Lavipharm plans to enter additional international markets, further expanding its product portfolio abroad.

Mr. Giannouleas concluded by underscoring Lavipharm's ongoing efforts to form new partnerships that maximize its production capacity and to explore opportunities to acquire pharmaceutical product dossiers, with the goal of enriching its portfolio in the near future.

CFO Vasilis Baloumis shared Lavipharm's 2024 financial results, which enabled the company to distribute a dividend of €0.02 per share for the first time in 18 years. He highlighted the significant improvement across all key financial indicators and outlined the

company's ambitious investment program, totaling €60 million for the 2022 to 2025 period, of which the majority has already been implemented. He emphasized that Lavipharm is among the leading players in the pharmaceutical sector, with its expanded production capacity in transdermal and liquid pharmaceuticals expected to further boost profitability, both from existing agreements and from those currently under negotiation.

Additionally, during the General meeting, all agenda items were discussed. A new Remuneration Policy and a new Suitability Policy were approved in accordance with current legislation. The Board's Audit Committee was re-elected, comprising Ms. Vasiliki (Vicky) Kefala as Independent Non-Executive Member, Mr. Christos Diamantopoulos as Non-Executive Member, and Mr. Antonios Polykandriotis as an independent third-party member. The Audit Committee's new one-year term will expire on July 3, 2026.

Finally, shareholders approved the company's revised Articles of Association, which include a change in share capital through the capitalization of funds from the "Share Premium Reserve" account. This move supports the free distribution of new shares to senior executives under the Stock Award Plan dated July 13, 2023.

###

For more information:

Corporate Communications

Vivienne Thomas

Tel. 2106691404

vthomas@lavipharm.com